Quantcast

Latest Methotrexate Stories

2008-11-07 09:00:24

Spectrum Pharmaceuticals, Inc., (NasdaqGM:SPPI) announced today that the Centers for Medicare and Medicaid Services (CMS), under the Medicare Part B benefit, has assigned a unique, product-specific billing code, or J-code, for FUSILEV(TM) (levoleucovorin). FUSILEV(TM) is the only commercially available formulation comprised only of the pharmacologically active isomer of leucovorin. The J-code J06410 becomes effective on January 1, 2009, and will assist providers in obtaining reimbursement for...

2008-10-31 09:00:08

Spectrum Pharmaceuticals, Inc., (NasdaqGM:SPPI) today announced that it has filed with the FDA the supplemental NDA for FUSILEV(TM) (levoleucovorin) for injection in combination with 5-FU containing regimens in advanced metastatic colorectal cancer. FUSILEV is the only commercially available formulation comprised only of the pharmacologically active isomer of leucovorin. "Ninety percent of the more than 500 million milligrams of leucovorin used in the United States is for colorectal...

2008-10-30 03:00:27

Chelsea Therapeutics International has completed patient enrollment in its Phase II trial comparing the efficacy and tolerability of daily oral doses of CH-1504, a metabolically inert antifolate, to a standard weekly dose of methotrexate in rheumatoid arthritis patients. A total of 200 patients were enrolled in this 12-week, four-arm, parallel group Phase II clinical trial designed comparing 0.25mg, 0.5mg and 1mg once daily oral doses of CH-1504 versus a 20mg once weekly oral dose of...

2008-10-28 09:00:07

CHARLOTTE, N.C., Oct. 28, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it has completed patient enrollment in its Phase II trial comparing the efficacy and tolerability of daily oral doses of CH-1504, a novel metabolically inert antifolate, to a standard weekly dose of methotrexate in rheumatoid arthritis patients. "Having recently received a favorable recommendation from an independent data safety monitoring board and now having completed...

2008-10-28 06:00:28

Hoffmann-La Roche has reported positive data from two Phase III studies which showed that patients who suffer from the debilitating and painful effects of rheumatoid arthritis achieved significant improvements in signs and symptoms when treated with Actemra alone or in combination with methotrexate compared with methotrexate alone. Results of the Radiate study, which evaluated difficult-to-treat patients who failed to respond to prior anti-tumor necrosis factor (TNF)-alpha therapies,...

2008-10-28 06:00:27

US-based Cypress Bioscience, a developer of therapeutics and personalized medicine services, has launched its first two personalized medicine services. According to the company, the initial personalized medicine services facilitate improved diagnostic, prognostic and therapeutic decision making for rheumatologists treating patients with rheumatoid arthritis (RA). Avise PG is a test that supports dose optimization and therapeutic decision making for patients taking methotrexate (MTX), a...

6640dc3bba8ec21e76404c7bc556b7531
2008-10-27 15:20:00

A new study suggests a simple monthly injection of an antibody drug might stop the progression of rheumatoid arthritis (RA) in half of all patients. The new drug, known as tocilizumab, works with methotrexate, an existing RA treatment.  Rheumatoid arthritis is a potentially crippling condition in which the body attacks its own joints.  Although nothing can be done to reverse existing damage caused by RA, the new research shows the two drugs taken together can achieve remission by...

2008-10-27 09:00:12

SAN FRANCISCO, Oct. 27 /PRNewswire/ -- Results from two Phase 3 studies showed that patients receiving every four week subcutaneous injections of golimumab (CNTO 148) 50 mg or 100 mg, an investigational therapy, experienced significant improvements in physical function, health-related quality of life (HRQOL) and fatigue. The data from the randomized, double-blind, placebo- controlled studies in patients with active moderate to severe rheumatoid arthritis (RA) were presented at the American...

2008-10-27 09:00:12

SAN FRANCISCO, Oct. 27 /PRNewswire/ -- 5:00 AM PST -- UCB announced today results from several Phase III clinical trials evaluating CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF (Tumor Necrosis Factor) - presented at the American College of Rheumatology (ACR) Annual Scientific Meeting. Results from the open-label extension study to RAPID 1 met both co-primary endpoints (American College of Rheumatology (ACR) 20 response(a) scores at Week 24 and change from baseline in modified...

2008-10-25 21:00:11

NUTLEY, N.J., Oct. 25 /PRNewswire/ -- One-year data from a two-year Phase III study demonstrated that ACTEMRA(R) (tocilizumab) significantly inhibited the progression of structural joint damage in patients with rheumatoid arthritis (RA). Late-breaking results from the LITHE study will be featured as an oral presentation during the American College of Rheumatology (ACR) Annual Scientific Meeting (October 24-28) in San Francisco. Fourteen additional abstracts, which evaluate ACTEMRA, a novel...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related